Several studies using experimental arthritis models [30–37] or pharmacological and genetic inhibition of PARP-1 in FLS from RA patients [38] have revealed the involvement of this protein in the pathogenesis of arthritis and the potential therapeutic effects of PARP-1 inhibition. Here, PARP1 is linked to rheumatoid arthritis.